Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants

Current Medicinal Chemistry
Torsten Steinmetzer, J Stürzebecher

Abstract

The trypsin-like serine protease thrombin is a multifunctional key enzyme at the final step of the coagulation cascade and is involved in the regulation of hemostasis and thrombosis. An increased activation of coagulation can result in severe thromboembolic disorders, one of the major reasons responsible for mortality and morbidity in western world. Therefore, an effective, safe, and orally available thrombin inhibitor could be a useful anticoagulant drug for the daily prophylaxis of venous and arterial thrombosis and prevention of myocardial infarction for high-risk patients. Synthetic thrombin inhibitors have a long history; initial compounds were derived from electrophilic ketone- and aldehyde-analogs of arginine. First potent leads of non-covalent inhibitors were developed in the early eighties, which were further optimised in the nineties, after the X-ray structure of thrombin became available. In the meantime a huge number of highly active and selective inhibitors has been published, however, only a few of them have an appropriate pharmacokinetic and pharmacodynamic overall profile, which could justify their further development. Very recently, with Ximelagatran a first orally available thrombin inhibitor has been approved...Continue Reading

Citations

Apr 24, 2012·Chemical Reviews·Reem SmoumMorris Srebnik
Jul 1, 2011·Journal of Medicinal Chemistry·Preetpal Singh SidhuUmesh R Desai
Dec 30, 2009·Journal of Medicinal Chemistry·Gero L BeckerTorsten Steinmetzer
Apr 3, 2007·Acta Crystallographica. Section F, Structural Biology and Crystallization Communications·Takayoshi KinoshitaRyota Kuroki
Jun 18, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Li-Wei HeNian-Guang Li
May 15, 2009·Scandinavian Journal of Immunology·P J Lachmann, R A G Smith
May 7, 2013·European Journal of Medicinal Chemistry·Uroš TrstenjakDanijel Kikelj
Dec 20, 2014·Biochimica Et Biophysica Acta·Eggert RühmannGerhard Klebe
Jun 13, 2009·Journal of Molecular Biology·Bernhard BaumGerhard Klebe
Feb 22, 2008·Bioorganic & Medicinal Chemistry Letters·Stephen HanessianOla Fjellström
Aug 14, 2009·Bioorganic & Medicinal Chemistry Letters·Stephen HanessianOla Fjellström
Mar 7, 2006·Bioorganic & Medicinal Chemistry Letters·Helmut MackH Wolfgang Höffken
Nov 18, 2005·Bioorganic & Medicinal Chemistry Letters·Stephen HanessianYafeng Xue
Aug 27, 2014·Bioorganic & Medicinal Chemistry Letters·Christophe ParsyDominique Surleraux
Nov 21, 2007·Organic & Biomolecular Chemistry·David BlombergJan Kihlberg
May 17, 2005·Journal of Thrombosis and Haemostasis : JTH·W Bode
Sep 12, 2009·Expert Opinion on Therapeutic Patents·Modesto de CandiaCosimo Altomare
Aug 26, 2015·ChemMedChem·Daniela HäußlerMichael Gütschow
Jun 7, 2006·The Journal of Biological Chemistry·Bin LiuRupert C Wilmouth
Jan 3, 2021·International Journal of Biological Macromolecules·Noora BarzkarReza Nahavandi
Feb 17, 2006·Journal of Medicinal Chemistry·Nigel HowardRob L M van Montfort
Aug 6, 2010·Journal of Medicinal Chemistry·Mihiret Tekeste SisayMichael Gütschow
Dec 19, 2019·Journal of Agricultural and Food Chemistry·Hanxiong LiuMing Du
Apr 22, 2018·Journal of Chemical Theory and Computation·Agastya P BhatiPeter V Coveney

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.